ArticleAcute medicine & surgery
Bickerstaff brainstem encephalitis developed quickly after COVID-19 infection.
Article in Acute medicine & surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Bickerstaff brainstem encephalitis developed quickly after COVID-19 infection.Acute medicine & surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bickerstaff brainstem encephalitis (BBE) is an autoimmune disease characterized by impaired consciousness, ophthalmoplegia, and ataxia. We report two cases of BBE following COVID-19. Case Presentation: Case 1: A 51-year-old male was diagnosed with COVID-19 4 days after fever. He had prolonged loss of consciousness, and developed ophthalmoplegia and ataxia. He was treated with steroids and immunoglobulin, which improved his consciousness. Case 2: A 28-year-old female was diagnosed with COVID-19 because of fever 4 days after contact with a COVID-19 patient. She suffered from prolonged loss of consciousness, ophthalmoplegia, and myoclonus. She was treated with steroids, immunoglobulin, and plasmapheresis, which ameliorated her consciousness. Conclusion: Both patients developed central nervous system (CNS) symptoms within a week of COVID-19 onset, indicating that BBE develops immediately after prior infection. This disease should be considered if CNS symptoms appear rapidly after COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.